New anticoagulants versus enoxaparin after hip/knee surgery

In this large meta-analysis of randomized trials of VTE prophylaxis after hip/knee surgery, compared to enoxaparin, the risk of symptomatic VTE was lower was rivaroxaban and similar with dabigatran and apixaban; but the risk of bleeding with higher with rivaroxaban, similar with dabigatran, and lower with apixaban. Overall, the treatments did not differ on net clinical outcome (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment